REM-001 Therapy for the treatment of serious cutaneous oncology indications.

This is an open-label, single cohort study to confirm dose, assessments and timing of response, to support future studies. The primary objective of the trial is to evaluate cutaneous tumor response within total target treatment field to REM-001 therapy assessed using standardized digital photography.

Click here for more information.